Wells Fargo’s Constellation Pharmaceuticals, Inc. CNST Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2021
Q3 | – | Sell |
-1,199
| Closed | -$40K | – | 7944 |
|
|
2021
Q2 | $40K | Sell |
1,199
-2,478
| -67% | -$63.1K | ﹤0.01% | 5650 |
|
|
2021
Q1 | $86K | Sell |
3,677
-23,138
| -86% | -$701K | ﹤0.01% | 5558 |
|
|
2020
Q4 | $772K | Sell |
26,815
-24,727
| -48% | -$622K | ﹤0.01% | 4211 |
|
|
2020
Q3 | $1.04M | Sell |
51,542
-6,090
| -11% | -$149K | ﹤0.01% | 3825 |
|
|
2020
Q2 | $1.73M | Buy |
57,632
+47,077
| +446% | +$1.7M | ﹤0.01% | 3371 |
|
|
2020
Q1 | $331K | Buy |
10,555
+3,472
| +49% | +$121K | ﹤0.01% | 4353 |
|
|
2019
Q4 | $334K | Sell |
7,083
-21,749
| -75% | -$628K | ﹤0.01% | 4668 |
|
|
2019
Q3 | $186K | Buy |
28,832
+14,895
| +107% | +$124K | ﹤0.01% | 5005 |
|
|
2019
Q2 | $171K | Buy |
13,937
+4,132
| +42% | +$46K | ﹤0.01% | 5059 |
|
|
2019
Q1 | $133K | Buy |
9,805
+9,195
| +1,507% | +$82.4K | ﹤0.01% | 5026 |
|
|
2018
Q4 | $2K | Buy |
610
+39
| +7% | +$235 | ﹤0.01% | 6228 |
|
|
2018
Q3 | $4K | Buy |
+571
| New | +$5.44K | ﹤0.01% | 6160 |
|
Wells Fargo's CNST Position: Q3 2021 in Review
Wells Fargo sold out of Constellation Pharmaceuticals, Inc. (CNST) in Q3 2021, closing a stake of 1,199 shares — an estimated $40K sold.
Wells Fargo first reported a position in CNST in Q3 2018 and held it in 12 quarters. The position peaked at $1.73M in Q2 2020. 0 funds tracked by Wall St. Rank hold CNST as of Q3 2021.
- Wells Fargo reported no remaining Constellation Pharmaceuticals, Inc. position as of Q3 2021 after selling out during the quarter.
- Wells Fargo sold 1,199 Constellation Pharmaceuticals, Inc. shares in Q3 2021, an estimated $40K.
- Wells Fargo first reported a position in Constellation Pharmaceuticals, Inc. in Q3 2018 and held it in 12 quarters.
- Wells Fargo's Constellation Pharmaceuticals, Inc. position peaked at $1.73M in Q2 2020.
- 0 funds tracked by Wall St. Rank held Constellation Pharmaceuticals, Inc. as of Q3 2021.
Based on Wells Fargo's 13F filing for Q3 2021, filed 15 Nov 2021.